PMID: 25731233Mar 4, 2015Paper

Intra-arterial infusion of IA-call® combined with oral anticancer drugs for recurrent hepatocellular carcinoma after liver resection

Gan to kagaku ryoho. Cancer & chemotherapy
Kenji WakayamaAkinobu Taketomi

Abstract

Continuous hepatic artery infusion chemotherapy for hepatocellular carcinoma (HCC) refractory to trans-arterial chemoembolization ( TACE) sometimes adversely affects the quality of life (QOL) of patients. Herein, we report a one-shot intraarterial infusion of cisplatin powder (IA-call®) combined with oral anticancer drugs for recurrent HCC refractory to TACE after liver resection.From July 2013, 4 patients who were diagnosed with recurrent HCC refractory to TACE after liver resection were treated with IA-call® infusions at 1-2 month intervals.Encapsulated tegafur-uracil (UFT-E) or sorafenib were administered sequentially.On average, IA-call® was administered 3.6 times per patient at a mean dosage of 93 mg per treatment. UFT-E was combined with the IA-call® infusion for 3 patients, and a sorafenib combination was used for 1 patient.In terms of the therapeutic effects of these regimens, we observed complete response (CR) in 1 patient, partial response (PR) in 2 patients, and progressive disease (PD) in 1 patient(response rate: 75%). Therefore, one-shot intra-arterial infusion of IAcall ® combined with oral anticancer drugs is an effective therapy for recurrent HCC while maintaining patients' QOL.

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.